Results 41 to 50 of about 15,824 (192)

In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations

Antibiotics, 2021
Ceftazidime/avibactam uniquely demonstrates activity against both KPC and OXA-48-like carbapenemase-expressing Enterobacterales. Clinical resistance to ceftazidime/avibactam in KPC-producers was foreseen in in-vitro resistance studies.
Snehal Palwe, Yamuna Devi Bakthavatchalam, Kshama Khobragadea, Arun S. Kharat, Kamini Walia, Balaji Veeraraghavan   +5 more
doaj   +1 more source

In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria [PDF]

, 2017
Background: Diazabicyclooctanes (DBOs) inhibit class A, class C and some class D β-lactamases. A few also bind PBP2, conferring direct antibacterial activity and a β-lactamase-independent ‘enhancer' effect, potentiating β-lactams targeting PBP3.
Livermore, David M, Mushtaq, Shazad, Vickers, Anna, Warner, Marina, Woodford, Neil   +4 more
core   +1 more source

Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae

Antibiotics, 2022
Background: Carbapenemase-producing Klebsiella pneumoniae and Escherichia coli have become a significant global health challenge. This has created an urgent need for new treatment modalities.
Karoline Knudsen List, Mette Kolpen, Kasper Nørskov Kragh, Godefroid Charbon, Stine Radmer, Frank Hansen, Anders Løbner-Olesen, Niels Frimodt-Møller, Frederik Boetius Hertz   +8 more
doaj   +1 more source

Antimicrobial Resistance: We Must Pursue a Collaborative, Global Approach and Use a "One Health" Approach. [PDF]

, 2019
Treating infection is a key part of the work of most clinicians [...]
Lipman, J, Lonsdale, DO
core   +1 more source

The Klebsiella pneumoniae carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam

Antibiotics, 2023
Klebsiella pneumoniae carbapenemase KPC is an important resistance gene that has disseminated globally in response to carbapenem use. It is now being implicated as a resistance determinant in Ceftazidime Avibactam (CAZ-AVI) resistance. Given that CAZ-AVI
Sona Garsevanyan, Miriam Barlow
doaj   +1 more source

identifying allosteric networks to fight antibiotics resistance [PDF]

, 2018
The rise of multi-drug resistance in bacterial pathogens is one of the grand challenges facing medical science. A major concern is the speed of development of β-lactamase-mediated resistance in Gram-negative species, thus putting at risk the efficacy of ...
Afsharikho, Hamidreza, Barnes, Melissa D., Bonomo, Robert A., Galdadas, Ioannis, Gervasio, Francesco L., Haider, Shozeb, Healy, Jess, Lovera, Silvia, Pérez-Hernández, Guillermo, Woodford, Neil   +9 more
core   +1 more source

The Rapid CarbaLux Combination Test to Uncover Bacterial Resistance and Heteroresistance Prior to Antibiotic Treatment

Diagnostics
Background/Objectives: In this proof-of-concept study, the objective was to evaluate the phenotypic CarbaLux combination rapid test in terms of guiding the therapy of infections caused by multidrug-resistant Gram-negative bacteria with carbapenemase ...
Hans Rudolf Pfaendler, Hans-Ulrich Schmidt   +1 more
doaj   +1 more source

All Roads Lead to Rome: Enhancing the Probability of Target Attainment with Different Pharmacokinetic/Pharmacodynamic Modelling Approaches

Antibiotics, 2023
In light of rising antimicrobial resistance and a decreasing number of antibiotics with novel modes of action, it is of utmost importance to accelerate development of novel treatment options.
Kashaf Khalid, Katharina Rox
doaj   +1 more source

Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients. [PDF]

, 2016
This study aimed to investigate the pharmacokinetics (PK), safety, and tolerability of a single dose of ceftazidime-avibactam in pediatric patients. A phase I, multicenter, open-label PK study was conducted in pediatric patients hospitalized with an ...
Armstrong, Jon, Arrieta, Antonio, Bishai, Raafat, Bradley, John S, Das, Shampa, Delair, Shirley, Edeki, Timi, Holmes, William C, Li, Jianguo, Moffett, Kathryn S, Mukundan, Deepa, Perez, Norma, Romero, José R, Speicher, David, Sullivan, Janice E, Zhou, Diansong   +15 more
core  

New antimicrobials [PDF]

, 2017
Since 2010 the new antimicrobials introduced have activity against resistant Gram negative bacteria, long half-lives against Gram positive bacteria, better activity against Clostridium difficile, and safer antifungal properties. Limiting factors to using
Roland, Will
core   +1 more source